Ångström AI vs Moderna

Side-by-side comparison of AI visibility scores, market position, and capabilities

Moderna leads in AI visibility (90 vs 40)
Ångström AI logo

Ångström AI

EmergingHealthcare

Medical Imaging AI

Angstrom AI is a medical imaging AI company applying computer vision to analyze radiology scans and pathology slides to assist radiologists and pathologists with diagnosis. HQ: San Francisco.

AI VisibilityBeta
Overall Score
C40
Category Rank
#377 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
38
Perplexity
41
Gemini
36

About

Angstrom AI is a medical AI company developing computer vision models for clinical imaging analysis — applying deep learning to radiology images (X-rays, CT scans, MRIs) and digital pathology slides to assist physicians in detection and diagnosis. The company's AI models are trained to identify specific findings (nodules, lesions, abnormalities) in medical images, providing radiologists and pathologists with highlighted regions of interest and preliminary analysis that supports their diagnostic workflow. AI-assisted reading reduces the time required per scan, improves consistency, and provides a quality check layer for findings that could otherwise be missed under time pressure.

Full profile
Moderna logo

Moderna

LeaderHealthcare Tech

Enterprise

mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.

AI VisibilityBeta
Overall Score
A90
Category Rank
#2 of 596
AI Consensus
83%
Trend
stable
Per Platform
ChatGPT
92
Perplexity
93
Gemini
89

About

Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.

Full profile

AI Visibility Head-to-Head

40
Overall Score
90
#377
Category Rank
#2
79
AI Consensus
83
stable
Trend
stable
38
ChatGPT
92
41
Perplexity
93
36
Gemini
89
45
Claude
96
40
Grok
95

Key Details

Category
Medical Imaging AI
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Capabilities & Ecosystem

Capabilities

Only Ångström AI
Medical Imaging AI

Integrations

Only Moderna
Moderna is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.